当前位置:首页 - 行情中心 - 津药药业(600488) - 财务分析 - 现金流量表

津药药业

(600488)

  

流通市值:46.19亿  总市值:46.19亿
流通股本:10.92亿   总股本:10.92亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,218,663,367.77588,032,410.833,111,885,744.942,402,794,214.8
  收到的税费返还53,204,040.8125,352,337.88130,545,239.24103,659,578.05
  收到其他与经营活动有关的现金26,218,774.8713,517,583.7367,824,902.149,012,291.93
  经营活动现金流入小计1,298,086,183.45626,902,332.443,310,255,886.282,555,466,084.78
  购买商品、接受劳务支付的现金692,847,075.55320,398,896.31,737,546,632.671,342,991,437.09
  支付给职工以及为职工支付的现金325,753,338.18200,652,166.69532,093,280.09394,677,434.36
  支付的各项税费101,416,404.6459,570,296.41270,400,851.45211,539,336.56
  支付其他与经营活动有关的现金157,868,786.0656,783,004.67200,843,324.17151,911,219.98
  经营活动现金流出小计1,277,885,604.43637,404,364.072,740,884,088.382,101,119,427.99
  经营活动产生的现金流量净额20,200,579.02-10,502,031.63569,371,797.9454,346,656.79
二、投资活动产生的现金流量:
  取得投资收益收到的现金1,685,119.85---
  处置固定资产、无形资产和其他长期资产收回的现金净额0-1,953,600.98500,948.98
  投资活动现金流入的平衡项目0-00
  投资活动现金流入小计1,685,119.85-1,953,600.98500,948.98
  购建固定资产、无形资产和其他长期资产支付的现金24,821,271.0811,207,769.4977,740,241.4350,819,921.19
  支付其他与投资活动有关的现金00400,000400,000
  投资活动现金流出小计24,821,271.0811,207,769.4978,140,241.4351,219,921.19
  投资活动产生的现金流量净额-23,136,151.23-11,207,769.49-76,186,640.45-50,718,972.21
三、筹资活动产生的现金流量:
  取得借款收到的现金311,129,071.2217,124,391.02780,489,561.6765,013,153.86
  筹资活动现金流入小计311,129,071.2217,124,391.02780,489,561.6765,013,153.86
  偿还债务支付的现金113,394,561.680,000,0001,198,691,554.17944,591,554.17
  分配股利、利润或偿付利息支付的现金117,020,264.245,120,325.89164,372,792.99158,291,769.23
  其中:子公司支付给少数股东的股利、利润--41,002,248.42-
  支付其他与筹资活动有关的现金37,025,528.793,043,027.234,942,145.494,871,075.69
  筹资活动现金流出小计267,440,354.6388,163,353.091,398,006,492.651,107,754,399.09
  筹资活动产生的现金流量净额43,688,716.57128,961,037.93-617,516,931.05-342,741,245.23
四、汇率变动对现金及现金等价物的影响2,042,172.74983,500.5215,891,129.1112,823,532.35
五、现金及现金等价物净增加额42,795,317.1108,234,737.33-108,440,644.4973,709,971.7
  加:期初现金及现金等价物余额594,566,597.63594,566,597.63703,007,242.12703,007,242.12
  期末现金及现金等价物余额637,361,914.73702,801,334.96594,566,597.63776,717,213.82
补充资料:
  净利润84,377,354.25-208,212,548.19-
  资产减值准备5,643,012.22-7,977,073.18-
  固定资产和投资性房地产折旧127,339,068.24-253,575,858.6-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧127,339,068.24-253,575,858.6-
  无形资产摊销23,343,618.15-43,099,941.6-
  长期待摊费用摊销0-0-
  处置固定资产、无形资产和其他长期资产的损失9,235.51-33,485.38-
  固定资产报废损失0-62,268.91-
  公允价值变动损失0-0-
  财务费用9,817,134.29-15,147,207.67-
  投资损失-2,465,706.88-9,091,758.55-
  递延所得税673,402.57-11,574,632.01-
  其中:递延所得税资产减少1,257,424.27-12,748,582.58-
    递延所得税负债增加-584,021.7--1,173,950.57-
  存货的减少-39,288,172.97-94,997,232.2-
  经营性应收项目的减少-234,385,286.1-77,306,730.04-
  经营性应付项目的增加44,560,417.86--152,148,563.32-
  其他0-0-
  债务转为资本0-0-
  一年内到期的可转换公司债券0-0-
  融资租入固定资产0-0-
  现金的期末余额637,361,914.73-594,566,597.63-
  减:现金的期初余额594,566,597.63-703,007,242.12-
  加:现金等价物的期末余额0-0-
  减:现金等价物的期初余额0-0-
  现金及现金等价物的净增加额42,795,317.1--108,440,644.49-
公告日期2025-08-232025-04-292025-03-272024-10-30
审计意见(境内)标准无保留意见
TOP↑